Skip to main content
. 2016 Jul 22;60(8):4630–4637. doi: 10.1128/AAC.00757-16

TABLE 1.

Overview of MICs for wild-type strains and evolved high-persistence clones of the ESKAPE pathogens

ESKAPE pathogen MICa (μg/ml)
AMK
 GEN
 TOB
 MEM
 CIP
 LEV
 RIF
 CST
 VAN
wt hip wt hip wt hip wt hip wt hip wt hip wt hip wt hip wt hip
P. aeruginosa 1 1 1 ND 0.5 0.5 1.024 0.512 0.032 0.032 ND ND ND ND 0.5 0.5 ND ND
S. aureus 32 ND 2 2 512 512 16b 16b 0.5 2 0.25 0.5 0.008 0.008 ND ND 0.5 0.5
A. baumannii 4 2 >256 ND 2 1 4.096 2.048 >32 >32 8 8 ND ND 0.5 0.5 ND ND
K. pneumoniae 1 2 0.125 ND 0.5 0.5 0.256 0.256 0.128 0.128 ND ND ND ND 2 2 ND ND
E. aerogenes 4 4 0.5 ND 2 1 1.024 1.024 0.064 0.032 ND ND ND ND 1 1 ND ND
E. faecium 8b ND 8c 8c 64c 64c 2.048b 2.048b 8 8 2 2 0.008b 0.008b ND ND 0.5 0.5
a

Bold values indicate clinical resistance according to EUCAST guidelines (clinical breakpoints, version 5.0, available at http://www.eucast.org). Abbreviations: AMK, amikacin; GEN, gentamicin; TOB, tobramycin; MEM, meropenem; CIP, ciprofloxacin; LEV, levofloxacin; RIF, rifampin; CST, colistin; VAN, vancomycin; wt, wild type; hip, high-persistence clone; ND, not determined.

b

No breakpoints have been defined.

c

EUCAST defines no aminoglycoside breakpoints for enterococci but instead classifies strains as having either low- or high-level intrinsic resistance to aminoglycosides on the basis of their gentamicin MICs. The aminoglycoside MICs of the E. faecium strain used in this study fell below the upper limit for low-level resistance (MIC ≤ 128 μg/ml).